Webinar
Precision in Gastrointestinal Parasitology Testing:
Streamlining Laboratory Workflows and Addressing the Hidden Burden of Misdiagnosis with FDA-Cleared, Multiplex PCR Detection
Presented by Dr Richard Smith
Director, US Technical Operations, Genetic Signatures
Gastrointestinal (GI) parasitic infections represent a persistent public health challenge, with an estimated 65 million cases annually in the United States alone. Traditional diagnostic methods, such as ova and parasite (O&P) examinations by microscopy, are labor-intensive, time-consuming, and often yield suboptimal sensitivity (less than 50%), particularly when only a single sample is tested. These limitations can contribute to laboratory inefficiencies, diagnostic and treatment delays, missed infections, prolonged patient symptoms, inappropriate treatment, and increased healthcare costs.
Recent advances in molecular diagnostics offer a transformative solution for GI parasite testing. Genetic Signatures’ EasyScreen™ Gastrointestinal Parasite Detection Kit leverages multiplex real-time PCR and proprietary 3base® technology to efficiently detect eight clinically relevant parasites from a single stool sample in a streamlined, automated workflow. This is the broadest FDA 510(k) cleared molecular solution available, targeting Giardia duodenalis, Cryptosporidiumspp, Cyclospora cayetanensis, Entamoeba histolytica, Dientamoeba fragilis, Blastocystis spp., Enterocytozoon bieneusi, and Encephalitozoon intestinalis.
This presentation will explore the operational and clinical advantages of adopting a broader syndromic molecular panel for GI parasite detection. Attendees will gain insights into:
- The epidemiology and burden of GI parasitic infections in the US.
- The limitations of traditional testing and the diagnostic challenges faced by clinicians and laboratories.
- The workflow benefits of automated molecular testing, including reduced hands-on time and faster turnaround.
- How molecular diagnostics improve detection rates, support timely and accurate treatment decisions, and improve patient outcomes.
By integrating automation, precision, speed, and accuracy into the diagnosis of GI parasites, this FDA-cleared solution addresses the hidden burden of misdiagnosis and offers a scalable, efficient approach for modern pathology laboratories.
Dr Richard Smith
Genetic Signatures
Dr Richard Smith is a seasoned molecular diagnostics expert with over 25 years of experience in clinical laboratory science, molecular biology, and technical operations. He currently serves as the Director of US Technical Operations at Genetic Signatures Ltd., a global molecular diagnostics company known for its proprietary 3base® technology and EasyScreen™ pathogen detection kits. Richard is a Diplomat in Laboratory Management and a certified Clinical Genetic Molecular Biologist, bringing a valuable blend of scientific rigor and operational leadership to the field. Prior to joining Genetic Signatures, he served as Head of Operations at the first organization to receive FDA approval for nucleic acid-based donor screening assays. Under his leadership, the program successfully screened millions of plasma units annually using PCR for up to five viral targets, maintaining this high-throughput operation for over a decade. Throughout his career, Richard has also worked as a molecular diagnostics consultant and technical advisor, contributing to assay development, validation, and implementation across various clinical and research settings. His expertise spans infectious disease diagnostics, regulatory affairs, and laboratory automation. Based in Los Angeles, California, Richard leads the US technical strategy and operations, supporting the deployment of advanced multiplex PCR assays for infectious disease detection. His role is pivotal in expanding Genetic Signatures’ footprint across North America, ensuring high standards of clinical performance and regulatory compliance. Richard’s enduring commitment to advancing molecular diagnostics continues to shape the future of clinical testing and public health.